viewEvgen Pharma PLC

Evgen Pharma PLC says 56 people recruited to its STAR-COVID 19 trial

Researchers will investigate whether the company's drug, SFX-01, can reduce the severity, or prevent the onset of acute respiratory distress syndrome

Evgen Pharma PLC -

Evgen Pharma PLC (LON:EVG) said 56 people have been recruited to its phase II/III STAR trial assessing its drug in patients with acute respiratory infections, including those with coronavirus (COVID-19).

Specifically, researchers will investigate whether SFX-01 can reduce the severity, or prevent the onset of acute respiratory distress syndrome (ARDS) in pneumonia patients.

SFX-01 stimulates, or ‘upregulates’ the Nrf2 pathway, which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during severe viral infection.

Preclinical work has shown this up-regulation of the Nrf2 pathway has the potential to reduce the severity of ARDS.

“We are greatly encouraged by recent academic papers which reinforce previous preclinical data showing the potential benefit to ARDS patients of up-regulating Nrf2 and hope that SFX-01 may be a valuable addition to the array of treatments that these seriously ill patients can receive,” said chief executive Huw Jones in a statement.

“We look forward to further updating the market as we progress through this important trial.,' he added.

In all, 300 people will take part in the trial, which will also assess safety data. The study is sponsored by the University of Dundee and funded by the charity Life Arc.

Quick facts: Evgen Pharma PLC

Price: 8.2 GBX

Market: AIM
Market Cap: £22.54 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Evgen Pharma PLC named herein, including the promotion by the Company of Evgen Pharma PLC in any Content on the Site, the Company receives from...



Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and...

Evgen Pharma PLC (LON:EVG) Chief Executive Dr Huw Jones talks to Proactive London following an abundance of news from the clinical-stage drug development company. Jones talks through the ‘STAR’ trial updates which now have a total of 56 patients in Dundee. The aim is to reach 100 patients, which...

on 25/1/21

2 min read